Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Mar 01, 2022 8:47pm
226 Views
Post# 34473338

RE:RE:RE:RE:Very difficult to be constructive

RE:RE:RE:RE:Very difficult to be constructiveTry to visualize yourself as Warren Buffett and ask yourself is this the strategy he would employ? 

If cancer works, the chance that you will be adding a "0" behind your $3 target is high. Don't be foolish. Even if your are tired, which we would all certainly understand, you still need to let logic guide your decisions and settling for $3 has a really good shot at being one of the dumbest things you ever did in your life. It is all about cancer and cancer looks pretty good right now. The FDA gave it Fast Track status, Soleus is interested enough to becomeTH's largest shareholder and to make it on of that cancer specialist money manager's largest holdings, the ex-Pfizer CMO was interested enough to join up with TH when he could go anywhere he wanted and Chinese drug companies are currently sparring with one another to gainthe right sto develop and market TH-1902 in China. So people who know a lot more than me or you clearly are validating that TH has a real shot at something special. And now we are 2-3 months away from another major milepost that could totally transform the trajectory of the stock. Don't let human emotions blind you to these facts.    

Trogarzon wrote:
They have a window to deliver between now and then it will come down on them with a vengence otherwise. They lost the luxury of time with most of the shareholders. At this point most prefer an exit strategy if nothing happens short term. I know that's the way I feel and the way I will vote. No more restructuring, rebuilding, retrying whatever did'nt work in the past, present or future. If they fail to accomplish anything short term I don't wan't another CEO, another Board.. I want a strategic review and a sale of the company for what they can get above 3$.


<< Previous
Bullboard Posts
Next >>